ConductScience.org, home

Paper7656502

Clinical pharmacokinetics of altretamine.

Damia G and 1 other. Clin Pharmacokinet, 1995. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Clinical pharmacokinetics of altretamine. Papers, record 7656502. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7656502

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical pharmacokinetics of altretamine.
PubMed
Journal
Clin Pharmacokinet
PubMed
Year
1995
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
0.69
iCite
Revised in PubMed
2018-11-13
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Damia GG
2D'Incalci MM

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AltretamineMajor topic
Administration, Oral
Animals
Biological Availability
Dose-Response Relationship, Drug
Humans
Infusions, Parenteral
Injections, Intravenous
Molecular Structure

Source PubMed

Download CSV of topics

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16781746Phase I study of pentamethylmelamine.Cancer Treat Rep1980https://conductscience.org/library/papers/6781746PubMed
2820422Hexamethylmelamine. An evaluation of its role in the therapy of cancer.Cancer1976https://conductscience.org/library/papers/820422PubMed
3117725Gas chromatographic determination of hexamethylmelamine in mouse plasma.Anal Biochem1979https://conductscience.org/library/papers/117725PubMed
44953645Phase I study of hexamethylmelamine (NSC-13875).Cancer Chemother Rep1965https://conductscience.org/library/papers/4953645PubMed
56778613Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine.Cancer Treat Rep1980https://conductscience.org/library/papers/6778613PubMed
66771004Comparative pharmacology of pentamethylmelamine and hexamethylmelamine in mice.Cancer Res1980https://conductscience.org/library/papers/6771004PubMed
76783296Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.Cancer Res1981https://conductscience.org/library/papers/6783296PubMed
82104537Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.Cancer Res1990https://conductscience.org/library/papers/2104537PubMed
9407012Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.Chem Biol Interact1977https://conductscience.org/library/papers/407012PubMed
102114821In vitro cytotoxicity of hexamethylmelamine (HMM) and its derivatives.Anticancer Res1990https://conductscience.org/library/papers/2114821PubMed
116417431Rapid formation of N-hydroxymethylpentamethylmelamine by mitochondria from rat small intestinal epithelium.Life Sci1983https://conductscience.org/library/papers/6417431PubMed
126401219Role of N-methylolpentamethylmelamine in the metabolic activation of hexamethylmelamine.Cancer Res1983https://conductscience.org/library/papers/6401219PubMed
13646928Variation in response of xenografts of colo-rectal carcinoma to chemotherapy.Br J Cancer1978https://conductscience.org/library/papers/646928PubMed
144748436N-demethylation of the antineoplastic agent hexamethylmelamine by rats and man.Cancer Res1973https://conductscience.org/library/papers/4748436PubMed
151904306Hexamethylmelamine: pharmacology and mechanism of action.Cancer Treat Rev1991https://conductscience.org/library/papers/1904306PubMed
166807543Parenteral formulation of hexamethylmelamine potentially suitable for use in man.Cancer Treat Rep1982https://conductscience.org/library/papers/6807543PubMed
174414651Metabolism of hexamethylmelamine-ring-14C in rats and man.Cancer Res1974https://conductscience.org/library/papers/4414651PubMed
18109196Variable oral absorption of hexamethylmelamine in man.Cancer Treat Rep1978https://conductscience.org/library/papers/109196PubMed
196428738Predictive testing with the subrenal capsule assay.Cancer Treat Rev1984https://conductscience.org/library/papers/6428738PubMed
201905441Altretamine.DICP1991https://conductscience.org/library/papers/1905441PubMed

See all 48 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
42504052Overcoming Radiation Resistance: Ferroptosis Induction to Sensitize Solid Tumors to Radiation Therapy.Cancer Med2026https://conductscience.org/library/papers/42504052PubMed
41599403Triazole and Pyrazole Hybrids of Electrophilic Natural Products as Promising Anticancer Agents.Molecules2026https://conductscience.org/library/papers/41599403PubMed
40867898Living on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target.Antioxidants (Basel)2025https://conductscience.org/library/papers/40867898PubMed
40807439Efficient Approaches to the Design of Six-Membered Polyazacyclic Compounds-Part 1: Aromatic Frameworks.Molecules2025https://conductscience.org/library/papers/40807439PubMed
39224646FDA-approved drugs containing dimethylamine pharmacophore: a review of the last 50 years.RSC Adv2024https://conductscience.org/library/papers/39224646PubMed
38613722Deciphering Ferroptosis: From Molecular Pathways to Machine Learning-Guided Therapeutic Innovation.Mol Biotechnol2025https://conductscience.org/library/papers/38613722PubMed
38590214A guide to ferroptosis in cancer.Mol Oncol2024https://conductscience.org/library/papers/38590214PubMed
37833746A review on the research progress of traditional Chinese medicine with anti-cancer effect targeting ferroptosis.Chin Med2023https://conductscience.org/library/papers/37833746PubMed
37559994Ferroptosis, a new form of cell death: mechanisms, biology and role in gynecological malignant tumor.Am J Cancer Res2023https://conductscience.org/library/papers/37559994PubMed
32606298The interaction between ferroptosis and lipid metabolism in cancer.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32606298PubMed
31936571Ferroptosis in Cancer Cell Biology.Cancers (Basel)2020https://conductscience.org/library/papers/31936571PubMed
31184303The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs.Elife2019https://conductscience.org/library/papers/31184303PubMed
29576720Synthesis, molecular docking, ctDNA interaction, DFT calculation and evaluation of antiproliferative and anti-Toxoplasma gondii activities of 2,4-diaminotriazine-thiazole derivatives.Med Chem Res2018https://conductscience.org/library/papers/29576720PubMed
15656694Interactions between antiretrovirals and antineoplastic drug therapy.Clin Pharmacokinet2005https://conductscience.org/library/papers/15656694PubMed
15568891Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.Clin Pharmacokinet2004https://conductscience.org/library/papers/15568891PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7656502

GET https://conductscience.org/api/papers/v1/7656502/references?page=2